Advertisement
Journal Home
Search for

Volume 65, Issue 3, Pages 274-283 (September 2009)


View previous. 5 of 24 View next.

Green tea, black tea consumption and risk of lung cancer: A meta-analysis

Naping TangaCorresponding Author Informationemail address, Yuemin Wub, Bo Zhouc, Bin Wangc, Rongbin Yud

Received 5 September 2008; received in revised form 1 December 2008; accepted 1 December 2008. published online 07 January 2009.

Abstract 

Studies investigating the association of green tea and black tea consumption with lung cancer risk have reported inconsistent findings. To provide a quantitative assessment of this association, we conducted a meta-analysis on the topic. Studies were identified by a literature search in PubMed from 1966 to November 2008 and by searching the reference lists of relevant studies. Summary relative risk (RR) estimates and their corresponding 95% confidence intervals (CIs) were calculated based on random-effects model. Our meta-analysis included 22 studies provided data on consumption of green tea or black tea, or both related to lung cancer risk. For green tea, the summary RR indicated a borderline significant association between highest green tea consumption and reduced risk of lung cancer (RR=0.78, 95% CI=0.61–1.00). Furthermore, an increase in green tea consumption of two cups/day was associated with an 18% decreased risk of developing lung cancer (RR=0.82, 95% CI=0.71–0.96). For black tea, no statistically significant association was observe through the meta-analysis (highest versus non/lowest, RR=0.86, 95% CI=0.70–1.05; an increment of two cups/day, RR=0.82, 95% CI=0.65–1.03). In conclusion, our data suggest that high or an increase in consumption of green tea but not black tea may be related to the reduction of lung cancer risk.

a National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, 199 Guoshoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, China

b Department of General Surgery, People's Hospital of Liyang City, Liyang, Jiangsu Province, China

c Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province, China

d Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China

Corresponding Author InformationCorresponding author. Tel.: +86 21 50800333; fax: +86 21 50801259.

PII: S0169-5002(08)00662-4

doi:10.1016/j.lungcan.2008.12.002


View previous. 5 of 24 View next.